logo
Plus   Neg
Share
Email

Inovio Gets $71 Mln DoD Contract To Scale Up Cellectra 3PSP Smart Device Manufacture

Inovio Pharmaceuticals Inc. (INO) said Thursday it has received $71 million funding from the U.S. Department of Defense or DoD to support the large-scale manufacture of the company's proprietary CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices, which are used to deliver INO-4800 directly into the skin.

INO-4800 is Inovio's DNA vaccine candidate being developed to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19.

CELLECTRA 3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to drive a robust immune response.

According to Inovio, interim results of U.S. Phase 1 clinical studies of INO-4800 will be available later this month. The company is planning a Phase 2/3 efficacy trial to begin this summer in July/August.

CELLECTRA 3PSP is a small, portable, hand-held, user-friendly device that runs on "AA" batteries. The device is designed to function reliably in challenging environments and can be stockpiled in large quantities without maintenance, characteristics that are critical in a pandemic situation.

While Inovio's San Diego device manufacturing facility has produced initial quantities of the device, the company has said that the design and scale-up of the manufacturing processes can be transferred to contract manufacturers to further increase supply.

The DoD contract, from the JPEO-CRBND-EB through funding provided by the Defense Health Program, builds upon two separate prior $5 million grants from the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations or CEPI, to accelerate the testing of CELLECTRA 3PSP.

Initial development of this next generation CELLECTRA 3PSP smart device started in 2019, with $8.1 million in funding from the medical arm of the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until March 31 in response to lower travel demand due to the coronavirus pandemic. This means that travelers are provided additional flexibility by not asking them to pay penalties for changing the origin and destination cities. Lancaster Foods LLC has recalled certain conventional processed butternut squash items citing the potential to be contaminated with Listeria Monocytogenes, the U.S. Food and Drug Administration said. The products recalled included Autumn Medley, Butternut Squash Noodles, Butternut Squash Planks, Squash Noodle Medley, Butternut Squash Chunks, and Veggie Rice Blend in various measures. Amazon.com Inc. has offered to help the newly sworn-in US President Joe Biden with speedy delivery of Covid-19 vaccines across the United States amid the ongoing pandemic crisis. The e-commerce giant, whose majority of workers are in the frontline of the pandemic, reiterated its request to prioritize its essential workers to receive the vaccines at the earliest appropriate time.
Follow RTT